CDT Equity Inc. (CDT) · Oct 13, 2026 · New debt

CDT Equity new debt brings cash but locks in dilution

New debt — $2.87M net first tranche; conversion at 70% of lows with $0.18354 floor

CDT Equity’s new debt provides an immediate cash bridge, but the terms prioritize repayment, enable discounted conversion, and force Nasdaq compliance actions.

CDT is a biopharma development company pursuing therapeutic assets and strategic partnerships, but this filing shows the immediate business problem is liquidity rather than clinical execution. There is no clean published consensus for a financing; against the standing situation, this is a cash bridge secured by unusually restrictive terms.

Item	Filing detail
First-tranche cash received	$3.00M gross; $2.87M net (Note, Funding Amount)
Debt principal created	$4.05M initially; up to $6.75M if the second tranche closes (Note, Original Principal Amount)
Initial repayment	$168,750 weekly for 24 installments, beginning October 14, 2026 (Note, Section 2(a))
Second tranche	$2.00M cash for another $2.70M of principal, conditional on registration, shareholder approval, no default and a $3.00 bid price (Note, Section 2(n))
Conversion terms	70% of the lowest 20-day closing price, subject to a $0.18354 floor that can reset lower (Note, Section 2(j))
Warrant	225,000 shares at $0.9177, exercisable immediately for five years (Note, Warrant disclosure)
Existing debt	$2.68M balance accruing at 24% compounded daily (Note, Section 2(g))

The financing keeps the company funded, but it is expensive liquidity rather than growth capital. CDT received only $2.87 million of usable cash against $4.05 million of initial principal. The first weekly payment starts almost immediately, and the second tranche is not committed cash: it requires a registration statement, shareholder approval, no event of default and a $3.00 closing bid price for five trading days.

The lender receives a broad path to repayment through discounted stock issuance. The conversion price is set at 70% of the lowest closing price over the prior 20 trading days, subject to a floor that can reset downward whenever the company issues cheaper securities. That structure makes future equity issuance a core repayment mechanism, not merely a backup. CDT also must direct 80% of ATM proceeds to this note first, then to the existing note, while 100% of proceeds from many other financings must prepay the new debt (Note, Sections 2(e) and 2(g)).

The note adds a near-term Nasdaq emergency to the capital problem. The agreement says the closing bid was already below Nasdaq’s $1.00 minimum and requires the company to pursue another reverse split, with effectiveness required by October 21, 2026 if the breach period continues. Failure to comply, or receiving a deficiency notice, is itself an event of default.

The financing protects the lender ahead of the operating business. It is secured by a first-priority lien, ranks senior to other company debt, carries a 120% default amount plus 24% compounded daily interest after default, and gives the lender control over financing proceeds. The company also acknowledges that the existing note continues accruing 24% default interest, so this transaction postpones pressure rather than resolving the debt burden.

Bottom line: This buys CDT short-term cash and preserves a path to keep operating, but it materially tightens the company’s financing constraints and makes discounted equity issuance, a reverse split and lender-directed cash flows central to the story. The event matters because it signals survival financing, not a strengthening of the underlying biopharma business.

What to watch next

Nasdaq compliance reverse split, by October 21

Original filing on SEC EDGAR

More CDT Equity Inc. news

Live · an AI on the whole US market

Breaking down Wall Street's information edge.

A buy-side analyst on every ticker.

It reads every public company's filing the second it drops — decoded into plain English, before it's a headline. The edge every investor deserves, not just the desks.

Trade the facts, not the FOMO.

Every event

8-Ks decoded the moment they file

Every number

Fundamentals, valuation, quality

What's next

Earnings calendar + the analyst view

scroll ↓

From filing to your screen in seconds

AllSight is the fastest.

DETECT

The moment it files

Every public company, around the clock. The AI never blinks and never takes lunch — nothing to set up.

filed 9:41:03 · decoded 9:41:19

DECODE

Plain English — never a call.

The event, the numbers, how it sits vs. expectations — in seconds. The AI decodes it; you pull the trigger.

DELIVER

On your screen, before the bell

Overnight and premarket, it's already read everything. You walk into every session with the setup — not scrambling to find it.

Understand it like a Wall Street analyst. Explained like a friend.

the raw filing — read the original on SEC.gov↗

decoded▸

AllSight · BlackBerry Q2 FY27

Revenue $163.3M vs ~$144M expected; adjusted basic EPS $0.07 vs ~$0.04 consensus — a real upside surprise.Income statement
QNX revenue +27% to $80.3M; segment EBITDA $29.0M from $20.5M. “Record performance… core automotive.”Segment — QNX
Licensing jumped to $22.1M from $6.6M — it amplified the beat, but it's less recurring than QNX, so the quality sits in QNX.Segment — Licensing
FY27 guide lifted to $616–636M rev / $141–158M EBITDA, above the prior $594–621M / $119–139M framework.Guidance
QNX growth, margins, cash and a raised outlook all beat. But licensing amplified it and Secure Comms is flat — net retention 91% from 93%.Segment — Secure Comms

Know a company all the way down.

Not just one filing. AllSight profiles every public company end to end — the numbers, the quality, the insiders, the smart money, the Street. One page, nothing missed.

Price & every insider trade, plotted
A quality score ranked against every peer
40+ valuation & profitability multiples
Where each one sits in its 5-year range
Whole-market insider flow, in real time
Which superinvestors are holding it
Analyst consensus & price target

Live · — filings read this week

AllSight gives you an edge others can't.

One scan before the open, one after the close — every filing on every ticker, already decoded. You walk into every session fully prepared.

Not investment advice · a neutral translation you can check against the original SEC filing

allsight.ai

Events/ANDE/8-K · Earnings

8-K · Item 2.02 · Earnings

The Andersons — a record Renewables quarter that beat profit expectations

Filed Aug 3, 2026ANDE · NASDAQ

AllSight readBeatPriced in▲ 1.8% since filed · reaction agrees

adj. EPS $2.15 vs ~$1.48 consensus

This filing tests whether The Andersons' sharp profit increase reflects broad operating improvement or a one-off renewable-fuels boost. It also separates strong adjusted earnings and cash generation from the quarter's legal and impairment charges.

The quarter was substantially stronger than both last year and the published earnings expectation. Adjusted EPS reached $2.15, versus $0.24 a year earlier and above the published consensus of about $1.48; reported EPS was $1.65. Adjusted EBITDA more than doubled to $140 million, while sales slipped modestly — the improvement came from margins and operating performance rather than higher revenue. Financial Highlights · Statements of Operations

Q2 ($M, exc. per-share)	Q2 2026	Q2 2025	YoY
Sales & merchandising revenue	3,097.7	3,135.9	−1%
Net income (attributable)	56.6	7.9	+48.7
Diluted EPS	1.65	0.23	+1.42
Adjusted EPS	2.15	0.24	+1.91
Adjusted EBITDA	140.3	65.2	+75.1
Agribusiness adj. pretax	20.3	16.8	+3.5
Renewables adj. pretax	88.4	9.6	+78.8
Cash from operations	487.9	299.3	+188.6
Cash from ops (pre-WC)	112.9	42.9	+70.1

Renewables drove nearly all of the upside — the operating backdrop was strong, but the result also benefited materially from tax credits. Renewables' adjusted pretax income rose to $88 million on record production, stronger ethanol margins and merchandising gains. It also received $24 million of 45Z producer tax credits, so this was not solely a repeatable plant-margin improvement; the company did cite healthy export and domestic ethanol demand as supportive. Renewables — Record Q2 · Segment Data

Agribusiness improved, but it was a supporting contributor rather than the main earnings engine. Adjusted pretax income increased to $20 million as fertilizer margins improved and merchandising benefited from commodity-price volatility, despite lower fertilizer volumes. Agribusiness — Improved Q2 · Segment Data

Cash generation improved and funding capacity is comfortable, while reported earnings still absorbed meaningful non-core costs. Operating cash flow was $488 million ($113 million before working-capital changes); capital spending was $76 million. Adjusted EPS excludes $0.50 of legal-settlement, impairment and transaction items, so the $2.15 adjusted result runs ahead of the $1.65 reported. Leverage stays below the <2.5× debt-to-EBITDA target; no new quantified full-year outlook was given. Cash & Liquidity · Adjusted Net Income

Community sentiment · 612 votes

58% bullish

Bull 58%Neu 27%Bear 15%

AllSight

AllSight Pro

A buy-side analyst on every ticker — reading the whole market the second it moves.

It reads every public company's filing the instant it drops and hands you what it means — in plain English, before it's a headline.

The read itself

Not another feed. A buy-side analyst that never sleeps, on everything.

Whole-market breadthevery public company

Not the 20 names CNBC repeats. Every ticker that files — thousands of companies, one AI reading all of them.

Filed-to-decoded in secondsspeed

Filed 9:41:03, decoded 9:41:19. You've got the catalyst while the tape is still moving and the crowd's still on the headline.

Past the headlinedepth

What actually happened, the numbers that matter, how it sits vs what the Street expected, and what it sets up next.

Source-grounded & neutralrigor

Every read traces to the words in the actual filing — click to see them. A translation you can check, never a buy/sell call.

Zero effort to youconvenience

Plain English, one glance. Follow your stocks and the moment any of them files, it's in your pocket — no watching, no digging.

All of it, livePro

Free reads every session once it closes. Pro reads it the moment it files: the whole market, all day, every day.

And then — go deeper

From "what happened" to "is it worth it."

Cheap or dear?Where it trades vs its own valuation history.

The quality score, in fullAll five dimensions, ranked against its sector.

Structure & multi-year trendsRevenue, margins, cash — the hard numbers, decoded.

Insider activityWho inside the company is buying and selling.

Analyst price targetsWhere Wall Street says every name is headed.

The whole company, one pagePrice, ownership, the full read — on any ticker.

Hire your personal buy-side analyst.

Trade one usual slippage for a whole market's rhythm.

Free

forever

Every closed session, on the whole market. The live session and the deep company read stay Pro.

Monthly

$29/mo

billed monthly

Everything, live — every session the moment it files, plus the full company read. Flexible, month to month.

Best value · save 40%

Annual

$17.40/mo

$209 billed yearly

about one slippage a month

Same full access — the whole market live and every company — at the lowest price. 40% off the monthly.

Billed today. Powered by Stripe · AllSight never sees your card.

CDT Equity new debt brings cash but locks in dilution

What to watch next

More CDT Equity Inc. news

Breaking down Wall Street's information edge.